secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2021-12-09T23:59:59+00:00
Accession:  0001628280-21-024728
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia reports positive long-term safety data from AURORA 2 study of LUPKYNIS in lupus nephritis
--------------------------------------------------------------------------------

- 116 voclosporin-treated patients showed stable mean eGFR over 36 months; +2.7 mL/min increase from baseline vs control.
- Serious adverse event rates lower in voclosporin group (19% vs 24% control); no deaths vs 4 in control.
- Mean UPCR lower in voclosporin group at all time points over three years.
- Withdrawal rate lower in voclosporin group (12.9% vs 15.0% control); drug well tolerated overall.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021024728/0001628280-21-024728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021024728/auph-20211209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-024728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer